Replies to post #6995 on GTC Biotherapeutics (fka GTCB)

[genisi]

The PPL trial was the worst and BTW they used transgenic protein as you know.
Telecris trial which was not placebo controlled (CF patients):

http://clinicaltrials.gov/ct2/show/NCT00486837?term=Alpha1-antitrypsin+inhaled&rank=2

and the Baxter/Arriva which was a safety trial of inhaled
recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency:

http://clinicaltrials.gov/ct2/show/NCT00161707?term=Alpha1-antitrypsin+inhaled&rank=3

Both did not continue with the inhaled program but a trend was seen and published:

http://www.ncbi.nlm.nih.gov/pubmed/17050563?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Kamada thinks that their ATT is better and that the Pari's device is superior. I personally think the odds are not high.